{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971699",
  "id": "02971699",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0830",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1lq98lg5d3z.pdf",
  "summary": "**Key Material Information from Nyrada Inc. Announcement (23 July 2025):**  \n\n- **Clinical Trial Progress**:  \n  - Phase IIa trial for **Xolatryp\u2122** targeting **acute myocardial infarction (AMI)** planned, focusing on **STEMI patients undergoing PCI**.  \n  - **Indicative design**: 150 patients, randomized, double-blind, placebo-controlled, testing two doses via 6-hour infusion.  \n  - **Targeted start**: Q1 2026 (pending Phase I completion and HREC approval).  \n\n- **Phase I Status**:  \n  - Final cohort dosed with **no adverse safety signals**; final data expected **September 2025 quarter**.  \n\n- **Strategic Focus**:  \n  - Priority shift to **cardioprotection** due to strong preclinical data and funding limitations for TBI/stroke programs.  \n\n- **Market Opportunity**:  \n  - **$11.7B global PCI market (2024)**, growing at **10.03% CAGR**; ~950,000 PCIs annually in the US.  \n\n- **Preclinical Efficacy**:  \n  - **86% cardioprotection** (6-hour treatment) and **42% efficacy** (3-hour treatment) in infarct models.  \n  - Neuroprotection data in stroke/TBI (statistically significant results).  \n\n**No capital raising, trading halt, or financial data disclosed.**",
  "usage": {
    "prompt_tokens": 2730,
    "completion_tokens": 290,
    "total_tokens": 3020,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:51:09.865783"
}